AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,302.50GBp
3:39am EDT
Price Change (% chg)

-42.00p (-0.97%)
Prev Close
4,344.50p
Open
4,312.00p
Day's High
4,325.00p
Day's Low
4,291.00p
Volume
251,587
Avg. Vol
3,354,393
52-wk High
4,946.41p
52-wk Low
3,085.21p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.35
Market Cap (Mil.): £55,114.09
Shares Outstanding (Mil.): 1,262.56
Dividend: 116.80
Yield (%): 4.05

Financials

  AZN.L Industry Sector
P/E (TTM): 45.25 35.82 36.29
EPS (TTM): 0.96 -- --
ROI: 5.15 18.85 18.13
ROE: 9.37 19.57 18.95
Search Stocks

AstraZeneca steps up push into cancer immunotherapy

LONDON - AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types.

31 Jul 2014

AstraZeneca steps up push into cancer immunotherapy

LONDON, July 31 - AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumour types.

31 Jul 2014

AstraZeneca raises forecasts after seeing off Pfizer

LONDON - AstraZeneca raised its sales and earnings forecasts for the year on Thursday, showing resilience after seeing off a $118 billion takeover approach from rival Pfizer two months ago.

31 Jul 2014

UPDATE 3-AstraZeneca raises forecasts after seeing off Pfizer

* Now assuming generic Nexium in U.S. from Oct. 1 (Adds CEO comments from conference call, further analyst comment)

31 Jul 2014

AstraZeneca smashes forecasts in Q2 after seeing off Pfizer

LONDON, July 31 - AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

31 Jul 2014

AstraZeneca buys Almirall lung drugs for up to $2.1 billion

LONDON - AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion for the rights to Spanish group Almirall's lung drugs.

30 Jul 2014

AstraZeneca buys Almirall lung drugs for up to $2.1 billion

LONDON - AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion for the rights to Spanish group Almirall's lung drugs.

30 Jul 2014

UPDATE 3-AstraZeneca buys Almirall lung drugs for up to $2.1 billion

* Initial $875 mln payout, up to $1.22 bln more if goals hit

30 Jul 2014

Almirall says in deal with Astrazeneca over respiratory business

MADRID, July 30 - Spain's Almirall on Wednesday said it had reached a deal to transfer to Astrazeneca the rights of its respiratory franchise for an initial $875 million. (Reporting by Julien Toyer; Editing by Tracy Rucinski)

30 Jul 2014

BRIEF-AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology study

* AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology clinical study

30 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks